RxDoctor Payments Data

Frank Hwang, MD

Ophthalmology · Loma Linda, CANPI 1548433600

Payments from drug & device makers

$2,517in general payments, 2019–2025

Across 71 payments — averaging $35.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Carl Zeiss Meditec USA, Inc.$176
  • Johnson & Johnson Surgical Vision, Inc.$152
  • AbbVie$131
  • Rxsight Inc$129
  • Organogenesis Inc.$108
  • plus $613 from 18 others

What the payments were for

  • Travel & lodging$141%
  • Food & beverage$2,50199%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,517 in reported general payments places this provider in the 60th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$188,706
Medicare patients
533
Services billed
1,208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine142$134,017
XiidraLifitegrast97$88,468
Cyclosporine109$49,763
Restasis MultidoseCyclosporine43$29,706
MieboPerfluorohexyloctane/Pf18$27,406
Prednisolone Acetate393$18,716
CequaCyclosporine14$13,647
TyrvayaVarenicline Tartrate21$13,017
RhopressaNetarsudil Mesylate19$11,857
Alphagan PBrimonidine Tartrate16$5,308
Loteprednol Etabonate20$4,593
ErythromycinErythromycin Base296$4,363
Brimonidine Tartrate43$3,508
Dorzolamide-TimololDorzolamide/Timolol/Pf18$3,376
Ketorolac Tromethamine85$2,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Restasis Multidose, Alphagan P$131$169,031201 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$68$115,874115 claims
Oyster Point Pharma, Inc.Tyrvaya$27$13,01721 claims
Aerie Pharmaceuticals, Inc.Rhopressa$24$11,85719 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$45$4,59320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Loma Linda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →